Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Clinical trials investigating venetoclax combinations for AML

Andrew Wei • 4 May 2018
ESH AL 2018
Acute Myeloid Leukemia Leukemia Venetoclax

Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses the early trials that are currently underway to evaluate the efficacy of the BH3 mimetic drug, venetoclax, in combination with intensive chemotherapy, MDM2 inhibitors and MEK inhibitors for the management of acute myeloid leukemia (AML). Dr Wei also explains how research into venetoclax has shifted, with a focus on the molecular characteristics of the patients that have received the drug. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

More from Andrew Wei

TP53 mutation in AML
Andrew Wei et al. • 4 Sep 2023
6:41
Clinical trials aiming to reduce the toxicity of novel agents in AML
Andrew Wei • 9 Dec 2022
6:14
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up
Andrew Wei • 15 Dec 2021
1:32
AML data at ASH 2021 and implications on clinical practice
Andrew Wei • 15 Dec 2021

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals